Literature DB >> 32551978

Formulation and investigation of pilocarpine hydrochloride niosomal gels for the treatment of glaucoma: intraocular pressure measurement in white albino rabbits.

Neelam Jain1, Anurag Verma2, Neeraj Jain3.   

Abstract

The present study was focused on investigating niosomal gels loaded with cholinergic drug; pilocarpine HCl, for prolonged precorneal residence time and improved bioavailability for glaucoma treatment. Pilocarpine HCl niosomes were prepared using various nonionic surfactants (span 20, span 60 and span 80), in the presence of cholesterol in different molar ratios by ether injection method. The selected formulations were incorporated into carbopol 934 and locust bean gum-based gels. TEM analysis confirmed that niosomes formed were spherical in shape and has a definite internal aqueous space with uniform particle size. Formulation F4 composed of span 60 and cholesterol (1:1) gave the highest entrapment (93.26 ± 1.75%) and slower release results after 8 hours (Q8h = 60.35 ± 1.87%) among other formulations. The in-vitro drug permeation studies showed that there was a prolonged release of drug from niosomal gels as compared to niosomes itself. Considering the in-vitro drug release, niosomal gel formulation G2 was the best among the studied formulations. The release data were fitted to an empirical equation, which indicated that the release follows non-Fickian diffusion mechanism. The stability study revealed that incorporation of niosomes in gel increased their stability than the niosome itself. No signs of redness, inflammation, swelling or increased tear production were observed over the study period for tested formulation by Draize's test. The intraocular pressure (IOP) lowering activity of G2 formulation showed relative bioavailability 2.64 times more than bioavailability of marketed Pilopine HS® gel. These results suggest that the niosomal gels containing pilocarpine HCl are promising ocular carriers for glaucoma treatment.

Entities:  

Keywords:  Draize test; IOP; Niosomes; niosomal gel; pilocarpine HCl

Mesh:

Substances:

Year:  2020        PMID: 32551978     DOI: 10.1080/10717544.2020.1775726

Source DB:  PubMed          Journal:  Drug Deliv        ISSN: 1071-7544            Impact factor:   6.419


  6 in total

1.  Sustained release of brimonidine from BRI@SR@TPU implant for treatment of glaucoma.

Authors:  Yujin Zhao; Chang Huang; Zhutian Zhang; Jiaxu Hong; Jianjiang Xu; Xinghuai Sun; Jianguo Sun
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

2.  In Vitro and In-Eye Comparison of Commercial Pilocarpine Ophthalmic Solution and an Optimized, Reformulated Pilocarpine for Presbyopia Treatment.

Authors:  Mitchell A Jackson; Jaya Giyanani; Yumna Shabaik; Jeff Penzner; Anuradha V Gore; Michael R Robinson; George O Waring
Journal:  Ophthalmol Ther       Date:  2022-03-02

Review 3.  Recent Developments of Nanostructures for the Ocular Delivery of Natural Compounds.

Authors:  Malihe Sadat Razavi; Pedram Ebrahimnejad; Yousef Fatahi; Antony D'Emanuele; Rassoul Dinarvand
Journal:  Front Chem       Date:  2022-04-13       Impact factor: 5.545

4.  Concise Synthesis of Both Enantiomers of Pilocarpine.

Authors:  Theresa Schmidt; Niels Heise; Kurt Merzweiler; Hans-Peter Deigner; Ahmed Al-Harrasi; René Csuk
Journal:  Molecules       Date:  2021-06-16       Impact factor: 4.411

Review 5.  The Emerging Role of Topical Ocular Drugs to Target the Posterior Eye.

Authors:  Lixiang Wang; Mikael Ben Zhou; Hui Zhang
Journal:  Ophthalmol Ther       Date:  2021-07-04

6.  Sorafenib-loaded nanostructured lipid carriers for topical ocular therapy of corneal neovascularization: development, in-vitro and in vivo study.

Authors:  Qing Luo; Jingjing Yang; Haohang Xu; Jieran Shi; Zhen Liang; Rui Zhang; Ping Lu; Guojuan Pu; Ningmin Zhao; Junjie Zhang
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.